The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Spravato, which is derived from ketamine, is not a new drug—it first came on the ... urinary tract and bladder symptoms,” it ...

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

Johnson & Johnson, said in a news release. “For too long, health care providers have had few options to offer patients much-needed symptom improvement." The nasal spray was first approved by the ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

Spravato is a ketamine-derived nasal spray that is FDA-approved for treatment-resistant depression. The Johnson & Johnson drug has been on the market since 2019, but could only be prescribed ...

The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for treatment-resistant depression.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used ...